Accelrys Adds Laboratory Information Management System to Software Suite - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Accelrys Adds Laboratory Information Management System to Software Suite


The Accelrys Process Management and Compliance Suite has been expanded with the addition of the Accelrys Laboratory Information Management System (LIMS), the company announced in a press release. This system uses a process-driven approach, which focuses on laboratory, quality-control, and manufacturing processes, in contrast to the sample-driven approach used by traditional LIMS. This process-driven approach enables organizations to achieve repeatability and consistency of procedures, automatically qualify operational changes, and maintain a lower total cost of ownership.

"Traditional systems deployed to support laboratory operations today lack the flexibility to manage the change inherent in the hand-off between departments that drive the scientific innovation cycle," said IDC Health Insights Research Director Alan Louie, PhD., in the press release. "By coming at LIMS from the process execution standpoint, companies like Accelrys are taking a more holistic approach to managing data. This approach is well suited for lab operations that are trying to drive standardization across changing environments while still maintaining process repeatability and regulatory compliance."

The Accelrys LIMS integrates with Accelrys Electronic Laboratory Notebook (ELN), Accelrys Laboratory Execution System (LES), Accelrys Electronic Batch Records (EBR), Accelrys Discoverant process management informatics, and the Accelrys Enterprise Platform (AEP) for data exchange to provide an end-to-end informatics system that makes data accessible across an organization.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here